Revance Therapeutics, Inc. announced 11 clinical and non-clinical presentations for DaxibotulinumtoxinA for Injection (RT002) and the company’s unique proprietary peptide and formulation technology at TOXINS 2019, a leading international conference on neurotoxins to be held Jan. 16 through 19 in Copenhagen, Denmark. Revance’s scheduled presentations are: Podium Presentations: Pooled Results from Two Phase 3 Pivotal Studies of DaxibotulinumtoxinA for the Treatment of Glabellar Lines (Jan. 17, 4:30 pm CET, Clinical Workshop 1B). Presenter: Dr. Steven G. Yoelin, Ophthalmologist at Steve Yoelin MD Medical Associates. Outcomes of Week-24 Completers and Subjects who had Follow-Up Beyond Week 24 after a Single Treatment of DaxibotulinumtoxinA; Results of a Phase 2 Open-Label Dose-Escalating Study in Isolated Cervical Dystonia (Jan. 18, 3:30 pm CET, Clinical Workshop 3A). Presenter: Dr. Atul Patel, Kansas City Bone & Joint Clinic. Poster Presentations (Jan. 17 and 18, noon to 2:30 pm CET). Aesthetics: Pooled Results from Two Phase 3 Pivotal Studies of DaxibotulinumtoxinA for the Treatment of Glabellar Lines. Results of a Large Open-Label Safety Study of DaxibotulinumtoxinA in Glabellar Lines. A Head-to-Head Dose-Ranging Study of DaxibotulinumtoxinA in the Treatment of Glabellar Lines: Results of the BELMONT Study. Therapeutics: Immunogenicity of DaxibotulinumtoxinA in Adults with Cervical Dystonia from a Phase 2 Dose-Escalation Multicenter Study. Outcomes of Week-24 Completers and Subjects who had Follow-Up Beyond Week 24 after a Single Treatment of DaxibotulinumtoxinA: Results of a Phase 2 Open-Label, Dose-Escalating Study in Isolated Cervical Dystonia. Methodology of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel group, Dose-Ranging 36-week Multicenter Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for the Treatment of Upper Limb Spasticity in Adults after Stroke or Traumatic Brain Injury. Non-Clinical: Revance's Novel Peptide Excipient (RTP004) and its Role in Stabilizing DaxibotulinumtoxinA against Aggregation. Development of Cell-Based Potency Assay for Release and Stability Testing of Drug Substance and Drug Product. Non-Clinical Overview of DaxibotulinumtoxinA to Support Registration for Human Use. Novel Peptide Excipient RTP004 Enhances the Binding of Botulinum Neurotoxin, a Cell Binding Domain HC to Rat Brain Synaptosomes. Stabilizing Effect of RTP004 on Non-Specific Surface Adsorption in Drug Product Manufacturing of DaxibotulinumtoxinA.